Endu combined with concurrent chemotherapy and radiotherapy for stage IIB-IVA cervical squamous cell carcinoma patients

Table 3 Comparison of serum marker levels between the two groups before and after chemotherapy (mean ± SD)

Group	n	TK1 (pmol/L)		HE4 (pmol/L)		VEGF (pg/mL)		SCC-Ag (ng/mL)
		Before chemotherapy	After chemotherapy	Before chemotherapy	After chemotherapy	Before chemotherapy	After chemotherapy	Before chemotherapy	After chemotherapy
Test group	60	3.64 ± 0.95	1.27 ± 0.40	138.5 ± 29.5	81.4 ± 24.0	549.6 ± 98.3	235.1 ± 38.0	6.19 ± 2.04	1.76 ± 0.55
Control group	60	3.40 ± 1.03	1.58 ± 0.51	132.0 ± 32.7	98.0 ± 28.6	541.0 ± 88.6	284.2 ± 54.1	5.95 ± 2.23	2.34 ± 0.78
t		1.327	-3.705	1.143	-3.444	0.503	-5.753	0.615	-4.707
P value		0.187	0.000	0.255	0.001	0.616	0.000	0.540	0.000

TK1: thymidine kinase 1; HE4: human epididymis protein 4; VEGF: vascular endothelial growth factor; SCC-Ag: squamous cell carcinoma-associated antigen.